Navigation Links
Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Date:6/30/2008

Conference Call and Webcast Today at 1:00 pm ET / 10:00 am PT

SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has launched its first commercial product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system. Zingo is an easy-to-administer, single-use, needle-free system that reduces the pain associated with peripheral intravenous (IV) line placements and blood draws in children three to 18 years of age. Zingo works quickly, within one to three minutes, to relieve pain at the needle insertion site.

"Zingo is the first easy-to-administer, fast-acting local anesthetic that could lead to a paradigm shift in the approach to venous access procedures such as drawing blood and placing IV lines in children," said William T. Zempsky, M.D., Associate Professor, Department of Pediatrics, University of Connecticut; Associate Director, Pain Relief Program, Connecticut Children's Medical Center, Hartford, who led the pediatric trials of Zingo. "Because available topical anesthetic creams can take up to 30 to 60 minutes to work, healthcare providers have had to sacrifice patient comfort when performing the numerous peripheral venous access procedures that occur each day. Zingo will be a source of relief to both them and the children and parents they deal with every day."

"The commercial launch of Zingo is a major milestone that is notable both for our company and for patients. We are fully committed to driving successful market introduction for this exciting new product," said Michael L. Kranda, Anesiva's president and chief executive officer.

Driving Penetration and Uptake for Large Unmet Need

"We are initially focusing
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
2. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
3. Anesiva Announces First Quarter 2008 Financial Results
4. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
5. Anesiva Announces Expansion of Zingo Agreement in Europe
6. Anesiva Announces New Zingo Marketing and Distribution Agreement
7. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
8. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
9. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Best Sanitizers, Inc., the first company ... sanitizer, asks food processors and food handling professionals to ... they’re currently using to Best Sanitizers’ Alpet® E3 ... to fighting cross-contamination and the spread of pathogens in ... are key criteria that make a hand sanitizer most ...
(Date:8/28/2014)... are important devices in spintronics, an electronic which ... electrons but also on their spin and the ... electric into magnetic signals and vice versa. Recently, ... the Institute of Physics at Johannes Gutenberg University ... Prague, and Japan, has for the first time ...
(Date:8/28/2014)...  Next month, executives from clinical trial marketing firm BBK ... with Patient-Centered Clinical Trials 2014 , to be held ... , September 4-5. Patient recruitment experts Bonnie A. Brescia ... will share insights on the benefits of employing an effective ... from media to mobile apps – can be used to ...
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... Say Biovail seeing tide changing against management - with ... at meeting, secretly met to change rules, TORONTO, ... said that their lawyers will be in court today ... BVF ) Annual General Meeting,was illegally held and ...
... Md., June 25 Martek Biosciences,(Nasdaq: MATK ... of DHA-omega 3 essential for infant brain and ... in the new Pregnium prenatal,supplement from Walmark. Featuring ... at major retailers in the Czech Republic, Slovakia,and ...
... Pharmaceuticals to develop drug candidate for prevention and ... function in kidney transplantation, LONDON, June 25 ... that the U.S. Food and Drug Administration (FDA) ... Drug,application (IND) for an siRNA therapeutic product based ...
Cached Biology Technology:Eastern European Supplement Leader Walmark Launches Prenatal Product Featuring Martek's life'sDHA(TM) 2Eastern European Supplement Leader Walmark Launches Prenatal Product Featuring Martek's life'sDHA(TM) 3FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry 2FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry 3
(Date:8/28/2014)... for measuring and imaging how quickly blood flows in ... how drug abuse affects the brain, which may aid ... to better treatment options for recovering drug addicts. The ... Stony Brook University in New York, USA and the ... The Optical Society,s (OSA) open-access journal Biomedical ...
(Date:8/28/2014)... release is available in German . ... are now built with the help of sophisticated assembly lines. ... are an important part of these assembly lines. In the ... in various work stages arranged in a precise spatial and ... of the line. , The creation of such an assembly ...
(Date:8/28/2014)... northern California, and Alaska totaled 515 million board feet ... increase of more than 10 percent compared to the ... Northwest Research Station reported today. During this same period, ... 247 million board feet. , The total value of ... to $390 million in the same quarter, while the ...
Breaking Biology News(10 mins):This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Nanoscale assembly line 2Nanoscale assembly line 3West coast log exports up, lumber exports down in second quarter of 2014 2
... when they invade other tissues in the body could ... them, a research group led by led by Bradley ... and cellular biology reports in Nature Cell Biology ... Ciona intestinalis , the researchers discovered that even non-invasive ...
... 2011 Case Western Reserve University School of Medicine has received ... Resources, part of the National Institutes of Health (NIH), to ... (CF). CF is an inherited disease that causes thick, ... tract. The four-year NIH grant was awarded to Mitchell Drumm, ...
... in Seattle have worked to solve the mystery of why ... they return from the ocean to mate and spawn. In ... the team use models to estimate the potential impact ... decades ahead. Stricken coho salmon ( Oncorhynchus kisutch ) ...
Cached Biology News:Sea squirt cells shed light on cancer development 2Sea squirt cells shed light on cancer development 3Sea squirt cells shed light on cancer development 4CWRU receives $2.1 million NIH grant to expand cystic fibrosis research models 2Models show Coho salmon at risk in US urbanizing watersheds 2
...
... multi-channel focal drug delivery. Maintain bath temperature ... bath line while quickly switching 4 or ... Steady 37°C at 5 ml/minute flow rates ... Advanced auto-tuning temperature lock ...
...
... recombinant human angiogenin expressed in ... Physical form: Lyophilized from a ... phosphate buffered saline. Titertest ... Titertest values: capture ELISA ...
Biology Products: